Asthma glaucoma treatment

Relative contraindications to the use of anticholinesterase treatment include a history of cardiovascular disease, asthma, glaucoma, and gastrointestinal or genitourinary obstruction. Symptomatic treatment of tachyarrhythmias with propranolol may be considered P blockers, however, are less effective than physostigmine. 

Respiratory Disorders. Topically applied P-blockers can induce asthma or dyspnea in patients with preexisting chronic obstructive pulmonary disease. Clinicians should inquire about a history of pulmonary disorders before initiating glaucoma treatment with P-blockers. A history of restrictive airway disease also contraindicates the use of opioids for treatment of ocular pain. 

Q84 In patients with a history of asthma, latanoprost is a preferred first-line treatment in open-angle glaucoma. Latanaprost is available as eye drops and once-daily application in the evening is recommended. 

A9-Tetrahydrocannabinol (A9-THC) is considered to be the predominant compound in preparations of C. sativa (marijuana, hashish, bhang) that is responsible for the central nervous system effects in humans. The recognized central nervous system responses to these preparations include alterations in cognition and memory, euphoria, and sedation. Potential therapeutic applications of cannabis preparations that are of either historical or contemporary interest include analgesia, attenuation of the nausea and vomiting of cancer chemotherapy, appetite stimulation, decreased intestinal motility of diarrhea, decreased bronchial constriction of asthma, decreased intraocular pressure of glaucoma, antirheumatic and antipyretic actions, and treatment of convulsant disorders. These effects have been reviewed recently (Howlett, 1995). 

There are two features of the cannabinoids which may ultimately be of therapeutic importance. THC lowers intraocular pressure, which may be of benefit in the treatment of glaucoma. There is also evidence that THC is a moderately effective antiemetic agent. Such a discovery has led to the development of nabilone, a synthetic cannabinoid, as an antiemetic agent, but its use is limited because of the dysphoria, depersonalization, memory disturbance and other effects which are associated with the cannabinoids. Whether the bronchodilator action of THC will ever find therapeutic application in the treatment of asthma remains an open question. 

Epinephrine CCi, Ob P1.P2 Acute asthma Treatment of open-angle glaucoma Anaphylactic shock... 

Topical beta-blockers can precipitate asthma and therefore must not be used to treat this patient s glaucoma. Topical prostaglandin analogues (e.g. latanoprost drops) are used as first-line treatment of glaucoma together with a sympathomimetic agent, brimonidine, as an alternative to beta-blockers in asthmatic and COPD patients. 

Delta-9-THC and some synthetic analogs are used therapeutically, for example, for nausea and vomiting produced by antineoplastic chemotherapy, analgesic, anticonvulsant for epilepsy, anti-inflammatory agent, appetite stimulant for patients with AIDS, as well as treatment for conditions such as asthma and glaucoma. Synthetic cannabinoids used therapeutically include dronabinol, nabilone, and levonamtradol. 

Glaucoma represents a significant health problem with estimates that between 2 to 9 percent of the adult population worldwide suffers from increased intraocular pressure. Current therapy include use of so-called beta-blockers . These drugs however are not effective for all patients and often result in undesirable side effects that include lowered pulse rate, asthma and gastrointestinal problems. It thus would be desirable to have a new means for treatment of glaucoma. 

Marijuana is a controversial, versatile weed that grows nearly everywhere in the world. There are no conclusive medical studies indicating that it is especially harmful to the health or the psyche. On the other hand, there is increasing evidence that it may have a number of medical uses, including treatment of glaucoma, asthma, migraine, congestion, epilepsy, convulsions and nerves. 

Merck has been actively restructuring its lines of business that were not significant to its financial position, liquidity, or operations. The company s intent was to focus its resources more fully on its core human health and pharmaceutical benefit services. This led to the development of products for the treatment of heart failure, high blood pressure, high cholesterol, depression, osteoporosis, glaucoma, asthma, and ulcers to name a few. The company has also been a leader in over-the-counter products (e.g., antacids). 

---